MCID: MYL006
MIFTS: 64

Myeloid Leukemia

Categories: Rare diseases, Cancer diseases, Immune diseases, Genetic diseases, Blood diseases

Aliases & Classifications for Myeloid Leukemia

MalaCards integrated aliases for Myeloid Leukemia:

Name: Myeloid Leukemia 12 50 29 52 14 69
Myeloid Granulocytic Leukemia 12
Non-Lymphocytic Leukemia 12
Leukemia Myelogenous 12

Classifications:



Summaries for Myeloid Leukemia

Disease Ontology : 12 A leukemia that is located in myeloid tissue.

MalaCards based summary : Myeloid Leukemia, also known as myeloid granulocytic leukemia, is related to acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) and leukemia, acute myeloid. An important gene associated with Myeloid Leukemia is RUNX1 (Runt Related Transcription Factor 1), and among its related pathways/superpathways are Pathways in cancer and NF-kappaB Signaling. The drugs Bosulif and Gleevec have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased substrate adherent cell growth and growth/size/body region

Wikipedia : 72 Myeloid leukemia is a type of leukemia affecting myeloid... more...

Related Diseases for Myeloid Leukemia

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Acute Myeloid Leukemia, Flt3-Related
Acute Myeloid Leukemia, Kit-Related Npm1-Related Acute Myeloid Leukemia
Acute Myeloid Leukemia with T(9;11)(p22;q23) Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 432)
id Related Disease Score Top Affiliating Genes
1 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) 34.4 FLT3 KIT
2 leukemia, acute myeloid 33.2 FLT3 GATA2 HOXA9 KIT MECOM MLF1
3 acute myocardial infarction 30.3 BCR MCL1 RUNX1
4 hemolytic anemia 29.2 ABL1 BCR FLT3 GATA2 KIT MECOM
5 atypical chronic myeloid leukemia 12.4
6 cytogenetically normal acute myeloid leukemia 12.3
7 core binding factor acute myeloid leukemia 12.3
8 familial acute myeloid leukemia with mutated cebpa 12.2
9 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 12.1
10 acute myeloid leukemia with recurrent genetic anomaly 12.1
11 unclassified acute myeloid leukemia 12.1
12 philadelphia-negative chronic myeloid leukemia 12.0
13 therapy related acute myeloid leukemia and myelodysplastic syndrome 12.0
14 acute myeloid leukemia with minimal differentiation 12.0
15 acute myeloid leukemia with t(9;11)(p22;q23) 12.0
16 acute myeloid leukemia with t(8;16)(p11;p13) translocation 12.0
17 acute myeloid leukemia with t(6;9)(p23;q34) 12.0
18 leukemia, chronic myeloid, somatic 11.9
19 cebpa-associated familial acute myeloid leukemia 11.9
20 leukemia 11.8
21 acute myeloid leukemia, flt3-related 11.8
22 acute myeloid leukemia, kit-related 11.8
23 acute myeloid leukemia, somatic dnmt3a-related 11.8
24 acute myeloid leukemia, susceptibility, gata2-related 11.8
25 npm1-related acute myeloid leukemia 11.8
26 acute myeloid leukemia and myelodysplastic syndromes related to radiation 11.8
27 megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13) 11.8
28 acute myeloid leukemia with npm1 somatic mutations 11.8
29 acute myeloid leukemia with 11q23 abnormalities 11.8
30 acute myeloid leukemia with t(8;21)(q22;q22) translocation 11.8
31 acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent 11.8
32 acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor 11.8
33 leukemia, acute promyelocytic, somatic 11.7
34 megakaryocytic leukemia 11.7
35 acute erythroid leukemia 11.6
36 myelodysplastic syndrome 11.5
37 aml with myelodysplasia-related features 11.5
38 mast-cell leukemia 11.4
39 myeloid sarcoma 11.4
40 myeloproliferative neoplasm 11.2
41 essential thrombocythemia 11.2
42 juvenile myelomonocytic leukemia 11.2
43 monocytic leukemia 11.2
44 acute monocytic leukemia 11.2
45 pulmonary alveolar proteinosis 11.2
46 medulloblastoma 11.2
47 ataxia-pancytopenia syndrome 11.1
48 pulmonary fibrosis and/or bone marrow failure, telomere-related, 1 11.0
49 pdgfrb-associated chronic eosinophilic leukemia 11.0
50 phosphoglycerate mutase deficiency 10.9 ABL1 BCR

Graphical network of the top 20 diseases related to Myeloid Leukemia:



Diseases related to Myeloid Leukemia

Symptoms & Phenotypes for Myeloid Leukemia

GenomeRNAi Phenotypes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.63 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.63 ABL1 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.63 ABL1 FLT3 KIT
4 Increased shRNA abundance GR00327-A 9.35 ERG FLT3 MCL1 MYH11 PTPN11
5 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 9.17 GATA2 MCL1 MLF1 NUP98 RUNX1 RUNX1T1

MGI Mouse Phenotypes related to Myeloid Leukemia:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.41 BCR CBFA2T2 CBFB ERG FLT3 GATA2
2 cellular MP:0005384 10.4 CBFA2T2 CBFB ERG FLT3 GATA2 KIT
3 hematopoietic system MP:0005397 10.32 CBFB ERG FLT3 GATA2 HOXA9 KIT
4 cardiovascular system MP:0005385 10.31 ABL1 CBFB ERG GATA2 KIT MECOM
5 endocrine/exocrine gland MP:0005379 10.3 ABL1 CBFA2T2 CBFB ERG FLT3 GATA2
6 immune system MP:0005387 10.3 ABL1 BCR CBFA2T2 CBFB ERG FLT3
7 embryo MP:0005380 10.28 ABL1 CBFB ERG GATA2 KIT MCL1
8 mortality/aging MP:0010768 10.27 ABL1 BCR CBFA2T2 CBFB ERG FLT3
9 digestive/alimentary MP:0005381 10.2 KIT MYH11 PTPN11 RARA RUNX1T1 ABL1
10 integument MP:0010771 10.09 MCL1 MECOM MYH11 PTPN11 RUNX1 RUNX1T1
11 liver/biliary system MP:0005370 10.06 ABL1 BCR CBFB GATA2 KIT MECOM
12 normal MP:0002873 10.03 ABL1 BCR CBFB ERG GATA2 KIT
13 hearing/vestibular/ear MP:0005377 9.97 RARA BCR GATA2 KIT MECOM PTPN11
14 neoplasm MP:0002006 9.92 CBFB ERG FLT3 KIT MECOM PTPN11
15 reproductive system MP:0005389 9.85 MCL1 MECOM PTPN11 RARA RUNX1T1 CBFA2T2
16 respiratory system MP:0005388 9.61 ABL1 CBFB ERG KIT MECOM MYH11
17 skeleton MP:0005390 9.28 ABL1 CBFB FLT3 HOXA9 KIT MECOM

Drugs & Therapeutics for Myeloid Leukemia

FDA approved drugs:

(show all 8)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Bosulif 17 46 BOSUTINIB MONOHYDRATE Pfizer September 2012
2
Gleevec 17 46 IMATINIB MESYLATE Novartis May 2001
3
Iclusig 17 46 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
4
Lynparza 17 46 OLAPARIB AstraZeneca December 2014
5
Mylotarg 17 46 GEMTUZUMAB OZOGAMICIN Wyeth May 2000
6
Sprycel 17 46 DASATINIB Bristol-Myers Squibb June 2006
7
Synribo 17 46 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical October 2012
8
Tasigna 17 46 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007

Drugs for Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 678)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
2
Idarubicin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 58957-92-9 42890
3
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
4
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
5
Daunorubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 20830-81-3 30323
6
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
7
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 320-67-2 9444
8
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2353-33-5 451668
9
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
10
Topotecan Approved, Investigational Phase 4,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
11
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 302962-49-8 3062316
12
Amsacrine Approved Phase 4,Phase 3,Phase 1,Phase 2 51264-14-3 2179
13
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
14
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 75614-87-8, 51-45-6 774
15
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
16
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
17
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
18 Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
19
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1 191732-72-6 216326
20
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 171228-49-2 147912
21
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
22
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
23
Nicotine Approved Phase 4 54-11-5 942 89594
24
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
25
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 3081921 477468
26 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1
27
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 2 67-97-0 6221 10883523 5280795
28
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
29
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
30
Lactitol Investigational Phase 4,Phase 2,Phase 3,Phase 1 585-86-4 3871
31
Aclarubicin Investigational Phase 4,Phase 2,Phase 1 57576-44-0 451415
32 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Topoisomerase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
40 Imatinib Mesylate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 123596
41 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
45 Hormones Phase 4,Phase 3,Phase 2,Phase 1
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
47 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
48 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1
49 topoisomerase I inhibitors Phase 4,Phase 2,Phase 1
50 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 2902)

id Name Status NCT ID Phase Drugs
1 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
2 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
3 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
4 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
5 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
6 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
7 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
8 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
9 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
10 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
11 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
12 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4 nilotinib
13 Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
14 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
15 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
16 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
17 Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
18 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
19 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients Completed NCT00180115 Phase 4 Cytarabine Dosage
20 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
21 An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4 Nilotinib
22 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Completed NCT00171899 Phase 4 imatinib mesylate
23 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
24 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Completed NCT01227577 Phase 4 Nilotinib
25 Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
26 Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
27 Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care Completed NCT00161668 Phase 4 Mylotarg
28 Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia Completed NCT00304447 Phase 4 Mylotarg
29 Tasigna in Glivec-resistant or Intolerant Patients in CML Completed NCT01206088 Phase 4 nilotinib
30 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed NCT00686543 Phase 4 Posaconazole
31 A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome Completed NCT01041846 Phase 4 No intervention
32 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
33 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
34 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
35 Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia Recruiting NCT02602314 Phase 4 Imatinib;Nilotinib
36 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Recruiting NCT03216070 Phase 4 Dasatinib 50 MG
37 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
38 Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
39 Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib Recruiting NCT02689440 Phase 4 Dasatinib
40 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Recruiting NCT02027064 Phase 4 Interferon-alpha
41 Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. Recruiting NCT02546674 Phase 4 Nilotinib
42 Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients Recruiting NCT02267993 Phase 4 recombinant human thrombopoietin
43 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
44 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
45 A Rollover Study to Provide Continued Treatment With Eltrombopag Recruiting NCT01957176 Phase 4 ELT
46 Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia Active, not recruiting NCT01819792 Phase 4
47 Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4 Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
48 Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Active, not recruiting NCT02228382 Phase 4 Bosutinib
49 A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients Active, not recruiting NCT02204722 Phase 4 600mg/day of Imatinib;400mg/day of Imatinib
50 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Active, not recruiting NCT01200355 Phase 4 micafungin;posaconazole

Search NIH Clinical Center for Myeloid Leukemia

Genetic Tests for Myeloid Leukemia

Genetic tests related to Myeloid Leukemia:

id Genetic test Affiliating Genes
1 Myeloid Leukemia 29

Anatomical Context for Myeloid Leukemia

MalaCards organs/tissues related to Myeloid Leukemia:

39
Myeloid, Bone, Bone Marrow, T Cells, Nk Cells, Testes, Breast

Publications for Myeloid Leukemia

Articles related to Myeloid Leukemia:

(show top 50) (show all 5889)
id Title Authors Year
1
Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia. ( 28152414 )
2017
2
Chemotherapy during Pregnancy: Cases of Hodgkin's and Non-Hodgkin's Lymphoma, Chronic Myeloid Leukemia, Breast Cancer, Nasopharyngeal Cancer, and Choriocarcinoma. ( 28700986 )
2017
3
FLT3 and JAK2 Mutations in Acute Myeloid Leukemia Promote Interchromosomal Homologous Recombination and the Potential for Copy Neutral Loss of Heterozygosity. ( 28108507 )
2017
4
Expression of embryonic stem cell markers in acute myeloid leukemia. ( 28718379 )
2017
5
Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. ( 28473620 )
2017
6
Acute Myeloid Leukemia With Inv(16)(p13q22) Associated With Hidden Systemic Mastocytosis: Case Report and Review of Literature. ( 28579854 )
2017
7
Acute Myeloid Leukemia in a Patient With X-linked Severe Combined Immunodeficiency. ( 28678090 )
2017
8
Long-term persistent donor-recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome. ( 28509586 )
2017
9
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. ( 28494506 )
2017
10
CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. ( 28031480 )
2017
11
Emerging therapies for acute myeloid leukemia: translating biology into the clinic. ( 28931762 )
2017
12
Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia. ( 28947392 )
2017
13
The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia. ( 28331964 )
2017
14
Subcellular localization of the FLT3-ITD oncogene plays a significant role in the production of NOX- and p22(phox)-derived reactive oxygen species in acute myeloid leukemia. ( 27870947 )
2017
15
Forced expression of Wnt antagonists sFRP1 and WIF1 sensitizes chronic myeloid leukemia cells to tyrosine kinase inhibitors. ( 28468589 )
2017
16
Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8. ( 28058493 )
2017
17
ATP-binding casette transporter expression in acute myeloid leukemia: association with in vitro cytotoxicity and prognostic markers. ( 28112576 )
2017
18
GATA2 Inhibition Sensitizes Acute Myeloid Leukemia Cells to Chemotherapy. ( 28114350 )
2017
19
E-26 Transformation-specific Related Gene Expression and Outcomes in Cytogenetically Normal Acute Myeloid Leukemia: A Meta-analysis. ( 28584213 )
2017
20
Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. ( 28399410 )
2017
21
Hydroxychloroquine sensitizes chronic myeloid leukemia cells to VI^9VI'2 T cell-mediated lysis independent of autophagy. ( 28339029 )
2017
22
Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation. ( 28184925 )
2017
23
Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients. ( 28679652 )
2017
24
Acute myeloid leukemia with mutated nucleophosmin 1 - an immunogenic AML subtype and potential candidate for immune checkpoint inhibition. ( 28935849 )
2017
25
Mycobacterium kansasii Pneumonia with Mediastinal Lymphadenitis in a Patient with Acute Myeloid Leukemia: Successful Treatment to Stem Cell Transplantation. ( 28271647 )
2017
26
Isolated thrombocytosis in chronic myeloid leukemia without significant leukocytosis. ( 28781272 )
2017
27
D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia. ( 28506695 )
2017
28
Development of Secondary Acute Myeloid Leukemia in a Pediatric Patient Concurrently Receiving Primary Therapy for Ewing Sarcoma. ( 28816792 )
2017
29
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. ( 28514758 )
2017
30
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. ( 28289867 )
2017
31
Myeloid leukemia factor-1 is a novel modulator of neonatal rat cardiomyocyte proliferation. ( 28087342 )
2017
32
The Semantics of Priapism and the First Sign of Chronic Myeloid Leukemia. ( 28638667 )
2017
33
C59T mutation in exon 2 of monocytic leukemia-associated antigen-34 gene indicates a high risk of recurrence of acute myeloid leukemia. ( 28693135 )
2017
34
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. ( 28556489 )
2017
35
Phe354Leu Polymorphism of LKB1 Is a Potential Prognostic Factor for Cytogenetically Normal Acute Myeloid Leukemia. ( 28882949 )
2017
36
Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients. ( 28383355 )
2017
37
Detection of a clone-specific GATA1 mutation to monitor treatment response and involvement of a monozygotic twin in myeloid leukemia of Down syndrome. ( 28074551 )
2017
38
Reduced ADAMTS-13 level negatively correlates with inflammation factors in plasma of acute myeloid leukemia patients. ( 28033504 )
2017
39
A unique set of complex chromosomal abnormalities in an infant with myeloid leukemia associated with Down syndrome. ( 28912835 )
2017
40
RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia. ( 28107692 )
2017
41
Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia. ( 28340577 )
2017
42
Outcome and Minimal Residual Disease Monitoring in t(16;21) Acute Myeloid Leukemia Patients Receiving Allogeneic Hematologic Stem Cell Transplantation. ( 28939454 )
2017
43
Cytogenetic and Cytogenomic Microarray Characterization of Chromothripsis in Chromosome 8 Affecting MOZ/NCOA2 (TIF2), FGFR1, RUNX1T1, and RUNX1 in a Pediatric Acute Myeloid Leukemia. ( 28085746 )
2017
44
Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. ( 28933735 )
2017
45
Effects of Pre- and Post-transplantation Minimal Residual Disease on Outcomes in Pediatric Patients with Acute Myeloid Leukemia Receiving Human Leukocyte Antigen-matched or Mismatched Related Donor Allografts. ( 28929514 )
2017
46
Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. ( 28918304 )
2017
47
Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma. ( 28368379 )
2017
48
Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. ( 28088653 )
2017
49
The functional polymorphisms of LIS1 are associated with acute myeloid leukemia risk in a Han Chinese population. ( 28076835 )
2017
50
KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia. ( 28792268 )
2017

Variations for Myeloid Leukemia

Expression for Myeloid Leukemia

Search GEO for disease gene expression data for Myeloid Leukemia.

Pathways for Myeloid Leukemia

GO Terms for Myeloid Leukemia

Cellular components related to Myeloid Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.56 ABL1 CBFB GATA2 MCL1 NUP98 RARA
2 nucleus GO:0005634 9.55 ABL1 CBFA2T2 CBFB ERG FLT3 GATA2

Biological processes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.99 CBFB ERG GATA2 MEIS1 RARA RUNX1
2 transcription from RNA polymerase II promoter GO:0006366 9.98 CBFB ERG GATA2 MEIS1 RUNX1
3 protein phosphorylation GO:0006468 9.91 ABL1 BCR ERG FLT3 KIT RARA
4 protein autophosphorylation GO:0046777 9.78 ABL1 BCR FLT3 KIT
5 peptidyl-tyrosine phosphorylation GO:0018108 9.76 ABL1 BCR FLT3 KIT
6 cell fate determination GO:0001709 9.58 GATA2 MCL1
7 hematopoietic stem cell proliferation GO:0071425 9.56 MECOM RUNX1
8 negative regulation of programmed cell death GO:0043069 9.55 KIT MECOM
9 regulation of response to DNA damage stimulus GO:2001020 9.54 ABL1 MCL1
10 platelet-derived growth factor receptor signaling pathway GO:0048008 9.54 ABL1 BCR PTPN11
11 Bergmann glial cell differentiation GO:0060020 9.52 ABL1 PTPN11
12 negative regulation of myeloid cell differentiation GO:0045638 9.5 GATA2 HOXA9 MEIS1
13 megakaryocyte development GO:0035855 9.43 KIT MEIS1 PTPN11
14 hemopoiesis GO:0030097 9.35 FLT3 GATA2 KIT MEIS1 RUNX1
15 myeloid progenitor cell differentiation GO:0002318 9.33 FLT3 KIT MLF1
16 definitive hemopoiesis GO:0060216 8.92 BCR CBFB GATA2 MEIS1
17 regulation of transcription, DNA-templated GO:0006355 10.19 ABL1 CBFA2T2 ERG GATA2 HOXA9 MECOM
18 transcription, DNA-templated GO:0006351 10.1 CBFA2T2 ERG GATA2 HOXA9 MECOM MEIS1
19 cell differentiation GO:0030154 10.04 ERG FLT3 GATA2 MCL1 MECOM MLF1

Molecular functions related to Myeloid Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.85 ABL1 CBFB ERG GATA2 MECOM MEIS1
2 sequence-specific DNA binding GO:0043565 9.8 ERG GATA2 HOXA9 MEIS1 RARA
3 protein domain specific binding GO:0019904 9.62 ABL1 MLF1 PTPN11 RARA
4 protein binding GO:0005515 9.62 ABL1 BCR CBFA2T2 CBFB ERG FLT3
5 protein tyrosine kinase activity GO:0004713 9.56 ABL1 BCR FLT3 KIT
6 transcription factor activity, sequence-specific DNA binding GO:0003700 9.56 CBFA2T2 CBFB ERG GATA2 MECOM RARA
7 regulatory region DNA binding GO:0000975 9.37 RARA RUNX1

Sources for Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....